France· FR:69497729
CEBESINE 0,4 %, collyre en solution
A medicinal product containing chlorhydrate d'oxybuprocaïne, registered in France by LABORATOIRE CHAUVIN.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CHLORHYDRATE D'OXYBUPROCAÏNE
- Manufacturer
- LABORATOIRE CHAUVIN
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009300926371 flacon(s) compte-gouttes polyéthylène basse densité (PEBD) avec fermeture de sécurité de 5 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Chlorhydrate d'oxybuprocaïne in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayOksybuprokain SASykehusapoteket Oslo, Rikshospitalet
- BelgiumMinims Oxybuprocaine Chlorhydrate 4 mg/mlBausch + Lomb Ireland
- FinlandMinims Oxybuprocaine HydrochlorideBausch + Lomb Ireland Limited
- NetherlandsMinims Oxybuprocainehydrochloride 4 mg/ml, oogdruppels, oplossingBausch + Lomb Ireland Limited
- SwedenObupro 4 mg/ml Ögondroppar, lösningAgepha Pharma s.r.o.
- IrelandMinims Oxybuprocaine Hydrochloride 0.4% w/v Eye Drops SolutionBausch + Lomb Ireland Limited
- CzechiaBENOXIUNIMED PHARMA spol. s r.o., Bratislava
- GermanyConjuncain® Edo®Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Benoxinat Zur Anästhesie In Der Oto-Rhino-Laryngologie, Novain
- Belgium · Minims Oxybuprocaine Chlorhydrate Bausch + Lomb Ireland Limited, Minims Oxybuprocaïnehydrochloride Bausch + Lomb Ireland Limited
- Bulgaria · Бенокси
- Czechia · Benoxi, Oxybuprocaine Olikla
- Germany · Conjuncain® Edo®, Novesine
- Denmark · Oftasen, Oxybuprocainhydrochlorid Agepha
- Estonia · Novain
- Spain · Oxibuprocaína Hidrocloruro Agepha
- Finland · Minims, Obupro 4 Mg/Ml Silmätipat, Liuos
- United Kingdom (Northern Ireland) · Oxybuprocaine Hydrochloride Alfa Intes
- Croatia · Ophtesia
- Hungary · Humacain, Oxybuprocaine Hydrochloride Agepha
- Ireland · Oxybuprocaine Agepha
- Iceland · Novain
- Italy · Benoxinato Cloridrato Intes, Novesina
- Lithuania · Novain
- Luxembourg · Conjuncain Edo, Minims
- Latvia · Oxybuprocaine Hydrochloride Agepha 4 Mg/Ml
- Netherlands · Minims, Monofree
- Norway · Obupro, Oxibuprokain Minims Bausch + Lomb Ireland Limited
- Poland · Novain, 4 Mg/Ml,
- Portugal · Anestocil, Novain 4 Mg/Ml Colírio,
- Romania · Benoxi, Oftacain
- Sweden · Novain, Oxibuprokain Bausch & Lomb
- Slovakia · Benoxi, Oxybuprocaine Olikla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a7afbfd7-3ae1-4e04-bc9e-ccb2cd66a699 GET /v1/drugs/a7afbfd7-3ae1-4e04-bc9e-ccb2cd66a699?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69497729",
"date_amm": "1997-07-17",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "CHLORHYDRATE D'OXYBUPROCAÏNE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "collyre en solution",
"voies_administration": "ophtalmique",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about chlorhydrate d'oxybuprocaïne.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.